(RTTNews) - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies ...

(RTTNews) - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies ...

Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes. The biopharmaceutical ...

Incyte (INCY) and Syndax (SNDX) announced that the FDA has approved Niktimvo in 9 mg and 22 mg vial sizes. The companies expect product to be available for order in the U.S. in early February ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. About 6% of Leqembi ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. Photo by Adobe Stock/HealthDay ...

In addition, replacing the 500 mg vial with a 250 mg presentation could lower the overall drug waste from 5.8% to 3.2%, creating up to $155 million in annul savings, the team found.

Change in Alzheimer's Drug Vial Size Could Be Big Money-Saver for Medicare By Dennis Thompson HealthDay Reporter MONDAY, Oct. 14, 2024 (HealthDay News) -- A simple tweak in available vial sizes of ...

Current vial sizes may result in 5.8% of the Alzheimer's disease drug being thrown away, representing $1,619 in wasted Medicare spending per patient per year, reported researchers led by John Mafi ...

Smaller vial size for Alzheimer's drug could save Medicare hundreds of millions per year Nearly 6% of Alzheimer's drug lecanemab is discarded, costing Medicare $1,600 per patient per year ...

Assuming conservative lecanemab uptake rates of 1.1–2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth ...

Assuming conservative lecanemab uptake rates of 1.1-2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth of ...